Suppr超能文献

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

作者信息

Dorff Tanya B, Tangen Cathy M, Crawford E David, Petrylak Daniel P, Higano Celestia S, Raghavan Derek, Quinn David I, Vogelzang Nicholas J, Thompson Ian M, Hussain Maha H A

机构信息

University of Southern California, Los Angeles, CA.

出版信息

Ther Adv Med Oncol. 2009;1(2):69-77. doi: 10.1177/1758834009343454.

DOI:10.1177/1758834009343454
PMID:21085622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2981166/
Abstract

The major goals of the SWOG-GU committee in the area of advanced prostate cancer are to improve the survival and quality of life of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

摘要

相似文献

1
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.
Ther Adv Med Oncol. 2009;1(2):69-77. doi: 10.1177/1758834009343454.
2
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
3
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
4
Prostate cancer clinical trials of the Southwest Oncology Group.
Oncology (Williston Park). 1997 Aug;11(8):1154-63; discussion 1163-70.
5
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
6
Future directions in the treatment of androgen-independent prostate cancer.
Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020.
7
Intermittent androgen deprivation therapy in advanced prostate cancer.
Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2.
8
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Oncologist. 2005;10 Suppl 3:30-9. doi: 10.1634/theoncologist.10-90003-30.
9
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
10
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
J Natl Cancer Inst. 2006 Apr 19;98(8):516-21. doi: 10.1093/jnci/djj129.

本文引用的文献

1
Cancer statistics, 2009.
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
2
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20.
3
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872.
4
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clin Genitourin Cancer. 2008 Sep;6(2):103-9. doi: 10.3816/CGC.2008.n.016.
5
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Cancer. 2008 Jun;112(11):2393-400. doi: 10.1002/cncr.23473.
6
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Cancer. 2007 Nov 1;110(9):1959-66. doi: 10.1002/cncr.22996.
7
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
J Urol. 2007 Nov;178(5):1946-51; discussion 1951. doi: 10.1016/j.juro.2007.07.026. Epub 2007 Sep 17.
8
EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.
Ann Surg. 1942 Jun;115(6):1192-200. doi: 10.1097/00000658-194206000-00030.
9
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Cancer Res. 2007 May 15;67(10):5033-41. doi: 10.1158/0008-5472.CAN-06-3332.
10
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Cancer Res. 2007 Apr 15;67(8):3818-26. doi: 10.1158/0008-5472.CAN-06-3879.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验